Hypocomplementemic Urticarial Vasculitis Syndrome Possibly Secondary to Etanercept Use

Fadahunsi, Angela; Garcia-Rosell, Melinda; Pattanaik, Debendra

doi:10.1097/rhu.0000000000000269

Cited by 6 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-C1q circulating antibodies are found in more than half of the patients and are, along with low C1q levels, considered to be the marker of the disease [ 5 , 6 , 11 , 12 ]. Apart from these, other factors that could possibly activate C1q are drugs, like the anti-TNF factor etanercept [ 14 ], viruses, like Epstein-Barr and Hepatits B,C [ 15 ] and other, non-identified autoantibodies [ 15 , 16 ]. Unfortunately, we could not test for anti-C1q antibodies, as the assay is not available not only in out hospital, but in any public laboratory in Greece.…”

Section: Discussionmentioning

confidence: 99%

A case report of hypocomplementemic urticarial vasculitis presenting with membranoproliferative glomerulonephritis

et al. 2020

View full text Add to dashboard Cite

Background: Hypocomplementemic urticarial vasculitis syndrome is an infrequent condition characterized by ocular, renal, gastrointestinal and pulmonary involvement with low serum complement levels and autoantibodies. Renal manifestations vary from microscopic hematuria to nephrotic syndrome and acute kidney injury. Accordingly differing histologic patterns have been reported. Case presentation: We present the case of a 65 years old woman with a history of chronic uveitis who presented with arthralgias, urticarial rush, nephrotic syndrome, glomerular hematuria and low serum complement. Kidney biopsy revealed an immune-complex membranoproliferative glomerulonephritis. The patient received induction therapy with steroids, cyclophosphamide and hydroxychloroquine followed by rapid clinical improvement and remission of proteinuria. Maintenance treatment consisted of rituximab pulses. Conclusions: The majority of hypocomplementemic urticarial vasculitis syndrome cases is idiopathic, although an association to drugs, infections or other autoimmune disorders has been recorded. Given the rarity and heterogeneity of the disease, no standard treatment is established.

show abstract

Section: Discussionmentioning

confidence: 99%

A case report of hypocomplementemic urticarial vasculitis presenting with membranoproliferative glomerulonephritis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Our literature search found only one case of HUV development during TNF‐α–blocking agent treatment, which involved psoriatic arthritis treatment with ETN . Moreover, Woody et al reported the case of a patient receiving CZP treatment for LCV .…”

Section: Case Descriptionmentioning

confidence: 98%

Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: A case report

et al. 2020

View full text Add to dashboard Cite

What is known and objective Tumour necrosis factor‐α–blocking agents potentially cause vasculitis. However, no study has reported on the association between hypocomplementemic urticarial vasculitis (HUV) and certolizumab pegol (CZP) usage. Case description We present the first case of HUV development during CZP treatment for rheumatoid arthritis. Hypocomplementemic urticarial vasculitis improved after CZP was discontinued and the dose of oral prednisolone was increased. What is new and conclusion Clinicians should be aware about the potential development of HUV during CZP treatment, which is presumed to be safe considering its unique structural characteristics that differ from those of other tumour necrosis factor‐α–blocking agents.

show abstract

Cutaneous vasculitis associated with molecular tergeted therapies: systematic review of the literature

Ozince

Onel

2022

Clin Rheumatol

View full text Add to dashboard Cite

Hypocomplementemic Urticarial Vasculitis Syndrome Possibly Secondary to Etanercept Use

Cited by 6 publications

References 4 publications

A case report of hypocomplementemic urticarial vasculitis presenting with membranoproliferative glomerulonephritis

A case report of hypocomplementemic urticarial vasculitis presenting with membranoproliferative glomerulonephritis

Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: A case report

Cutaneous vasculitis associated with molecular tergeted therapies: systematic review of the literature

Contact Info

Product

Resources

About